Radiation Therapy in 5 Sessions or Less

Complete your cancer treatment in 5 sessions or less

If you’ve been diagnosed with breast, prostate or lung cancer and radiation therapy is part of your treatment, you should know about important technology advance that can dramatically reduce your treatment time to just 5 days or less—with results that are as good or better than conventional radiation therapy that takes a lot longer.

Called accelerated hypofractionated radiation therapy (or precision stereotactic body radiation therapy), this breakthrough advanced treatment safely delivers higher doses of radiation during each treatment session. As a result, you can complete treatment in 5 or fewer daily sessions—compared to 25 to 45 sessions over 5 to 9 weeks with conventional radiation therapy.

This highly precise, sophisticated technology is now available at the Nuvance Cancer Institute at Norwalk Hospital as part of our partnership with the renowned Memorial Sloan Kettering (MSK) Cancer Center—giving you close-to-home access to today’s most advanced and effective therapies.

How accelerated hypofractionated radiation therapy works

When you undergo conventional radiation therapy for breast, prostate or lung cancer, your total radiation dose is divided into multiple small doses, called fractions, which generally are given once a day, 5 days a week, for 5 to 9 weeks.

 

In 2018, we introduced the first generation of hypofractionated radiation therapy Because this technology more precisely focused the radiation beam, we could better target the tumor while sparing nearby healthy tissue. As a result, we could substantially and safely reduce the number of treatment sessions and decrease overall treatment time by weeks.

 

Now, with further technology advances, we can focus the radiation beam with even greater precision. So we can further decrease the number of treatment sessions in many cases to 5 or fewer.

The benefits of accelerated hypofractionated radiation therapy

The notable benefits of this short-course approach to radiation therapy include:

  • It’s safe and effective—Research shows that accelerated hypofractionated radiation therapy delivers outcomes that are just as good—or better—than conventional radiation therapy
  • It’s more convenient—Because you can complete a full course of treatment in just 5 treatment sessions, you can take less time off from work, recover faster, and get back to your regular life sooner
  • There are fewer side effects—For example, men with prostate cancer experience a much lower risk of urinary incontinence and impotence compared with surgery

Who’s a candidate for accelerated hypofractionated radiation therapy?

A growing number of patients with breast, prostate and lung cancer are being treated with accelerated hypofractionated radiation therapy. In fact, it’s now considered a standard of care for treating appropriately selected patients with these types of cancer.

If you have breast, prostate or lung cancer and radiation therapy is part of your treatment, you will be carefully evaluated by our MSK-led radiation oncology team to determine if this treatment approach is right for you.

Why choose the Nuvance Cancer Institute at Norwalk Hospital for accelerated hypofractionated radiation therapy?

Memorial Sloan Kettering is a pioneer in treating cancer with radiation and was among the first cancer centers in the nation to use hypofractionated radiation therapy to treat certain types of cancer. Through our innovative collaboration with Memorial Sloan Kettering, MSK physicians and other staff are now available here at the Nuvance Cancer Institute at Norwalk Hospital—for your convenience, peace of mind, and the best-possible outcome.

Learn more about accelerated hypofractionated radiation therapy

Questions? Simply call us at (203) 845-4811 to learn more about this important new capability at the Nuvance Cancer Institute at Norwalk Hospital, or to schedule a consultation.


Sources

Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial [e-pub ahead of print]. Lancet. https://doi.org/10.1016/S0140-6736(19)31131-6, Accessed July 1, 2019.

Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer

MJ Zelefsky, A Pinitpatcharalert, M Kollmeier… - European urology …, 2019

Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis

TD Malouff, WC Stross, DS Seneviratne… - … cancer and prostatic …, 2019

Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies

WC Jackson, J Silva, HE Hartman, RT Dess… - International Journal of …, 2019

Katz AJ, Kang J. Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study. Front Oncol. 2014;4:301.

Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, et al. Stereotactic body radiotherapy for clinically localized prostate cancer: toxicity and biochemical disease-free outcomes from a multi-institutional patient registry. Cureus [Internet]. 2015. Available from: http://www.cureus.com/articles/3466-stereotactic-body-radiotherapy-for-clinically-localized-prostate-cancer-toxicity-and-biochemical-disease-free-outcomes-from-a-multi-institutional-patient-registry.

Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92(5):971–7.

Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97(5):976–85.